Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 357 Press Releases

Jul 28, 2015
The U.S. Food and Drug Administration has approved Praluent (alirocumab) Injection to treat high LDL Cholesterol in adult patients.

Jul 23, 2015
The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection...

Jul 21, 2015
Exelixis, Inc. has announced positive top line results from METEOR, the pivotal phase 3 trial evaluating COMETRIQ® (cabozantinib) in comparison to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have experienced disease...

Jul 14, 2015
Otsuka Pharmaceuticals and Lundbeck have received approval from the U.S.

Jul 08, 2015
The US Food and Drug Administration (FDA) has officially greenlighted Novartis’ heart failure drug Entresto(TM)  formerly known as LCZ696 to treat heart failure with reduced ejection fraction.

Jun 29, 2015
Novartis will acquire Spinifex Pharmaceuticals, a US and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain.

Jun 24, 2015
According to the “EvaluatePharma World Preview 2015, Outlook to 2020” report, prescription sales are expected to increase 5 percent annually over the next five years across the United States  and Europe.

Jun 22, 2015
The U.S. Food And Drug Administration (FDA) has approved Eisai’s antiepileptic agent Fycompa® (perampanel hydrate) to be used as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and...

Jun 17, 2015
Allergan plc has agreed to acquire KYTHERA Biopharmaceuticals, Inc for approximately $2.1 billion valued at $75 per KYTHERA share.

Jun 11, 2015
In a 13 to 3 vote, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S.



RSS Feed for NAPSRx Press Releases